American Capital Management Lowered Its Haemonetics (HAE) Stake; Intl Fcstone (INTL) Sentiment Is 1.65

February 15, 2018 - By Stephen Andrade

INTL FCStone Inc. operates as a financial services firm worldwide. The company has market cap of $753.78 million. The company's Commercial Hedging segment offers risk management consulting services related to agricultural and energy commodities, and base metal products listed on the London Metals Exchange. It currently has negative earnings. The Company’s Global Payments segment provides payment solutions to banks and commercial businesses; and charities and non-governmental organizations, and government organizations.

American Capital Management Inc decreased Haemonetics (HAE) stake by 2.71% reported in 2017Q3 SEC filing. American Capital Management Inc sold 11,900 shares as Haemonetics (HAE)’s stock rose 6.04%. The American Capital Management Inc holds 427,096 shares with $19.16M value, down from 438,996 last quarter. Haemonetics now has $3.72 billion valuation. The stock increased 0.56% or $0.39 during the last trading session, reaching $69.62. About 648,096 shares traded or 34.53% up from the average. Haemonetics Corporation (NYSE:HAE) has risen 45.56% since February 15, 2017 and is uptrending. It has outperformed by 28.86% the S&P500.

Private Capital Management Llc holds 4.19% of its portfolio in INTL FCStone Inc. for 717,825 shares. Punch & Associates Investment Management Inc. owns 545,077 shares or 1.85% of their US portfolio. Moreover, Cove Street Capital Llc has 1.71% invested in the company for 399,872 shares. The Connecticut-based Kokino Llc has invested 1.6% in the stock. Woodmont Investment Counsel Llc, a Tennessee-based fund reported 40,937 shares.

The stock increased 0.88% or $0.35 during the last trading session, reaching $40. About 95,876 shares traded. INTL FCStone Inc. (INTL) has risen 28.80% since February 15, 2017 and is uptrending. It has outperformed by 12.10% the S&P500.

Since January 2, 2018, it had 0 insider buys, and 1 sale for $448,434 activity. 7,118 Haemonetics Corporation (NYSE:HAE) shares with value of $448,434 were sold by KROLL MARK W.

Investors sentiment decreased to 1.28 in Q3 2017. Its down 0.42, from 1.7 in 2017Q2. It worsened, as 16 investors sold HAE shares while 60 reduced holdings. 33 funds opened positions while 64 raised stakes. 52.55 million shares or 2.13% less from 53.69 million shares in 2017Q2 were reported. Trexquant Invest Limited Partnership holds 10,302 shares or 0.12% of its portfolio. Amalgamated Savings Bank reported 7,172 shares. Loomis Sayles Company Limited Partnership has invested 0% in Haemonetics Corporation (NYSE:HAE). Carroll Finance Assoc, North Carolina-based fund reported 25 shares. Arrowstreet Lp invested in 154,861 shares. Jpmorgan Chase & Communication owns 85,562 shares. Riverhead Mgmt Ltd Limited Liability Company holds 0.01% or 3,971 shares in its portfolio. Moreover, Tci Wealth Advsrs has 0% invested in Haemonetics Corporation (NYSE:HAE) for 20 shares. Gemmer Asset Mngmt Limited Liability Company invested 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). Balyasny Asset Limited Liability Com reported 7,730 shares. Verition Fund Mngmt owns 5,738 shares. Renaissance Techs Limited Liability Corporation holds 0.05% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 876,207 shares. Ahl Partners Llp holds 0.09% or 108,976 shares. California Employees Retirement stated it has 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE). Pinebridge Limited Partnership invested 0.04% of its portfolio in Haemonetics Corporation (NYSE:HAE).

Among 10 analysts covering Haemonetics Corporation (NYSE:HAE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Haemonetics Corporation had 27 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Haemonetics Corporation (NYSE:HAE) has “Market Perform” rating given on Tuesday, September 20 by CJS Securities. Barrington Research upgraded it to “Outperform” rating and $41 target in Tuesday, November 8 report. Jefferies maintained Haemonetics Corporation (NYSE:HAE) on Thursday, August 31 with “Buy” rating. Morgan Stanley maintained the shares of HAE in report on Wednesday, February 7 with “Overweight” rating. The stock has “Hold” rating by Benchmark on Thursday, November 5. The firm earned “Market Perform” rating on Tuesday, January 2 by Raymond James. Goldman Sachs upgraded it to “Neutral” rating and $29 target in Monday, May 16 report. The company was maintained on Wednesday, May 11 by Benchmark. The company was maintained on Friday, October 6 by Morgan Stanley. The firm earned “Market Outperform” rating on Thursday, July 13 by JMP Securities.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>